Literature DB >> 12063825

Immunotherapy for pancreatic cancer: current concepts.

Howard L Kaufman1, Joseph Di Vito, Heidi Hörig.   

Abstract

Despite advances in chemotherapy and surgical technique, patients with pancreatic cancer often succumb to local recurrence or metastatic spread. The need for new therapeutic strategies for this disease coupled with a better understanding of basic immunology have led to the development of novel anti-tumor vaccines. This review focuses on the historical development of tumor vaccines emphasizing the identification of potential pancreatic tumor antigens. The role of both B-cell and T-cell responses in tumor rejection will be reviewed. Methods for antigen presentation, including peptides, recombinant viral and bacterial vectors, dendritic cells, and whole cell approaches will be discussed. The use of immune adjuvants and improved methods of vaccine delivery will also be explored. The full potential for the immunotherapy of pancreatic cancer awaits the results of early phase clinical trials. The development of pancreatic cancer vaccines represents a useful paradigm for the translation of basic research into the clinical arena.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12063825     DOI: 10.1016/s0889-8588(01)00002-8

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  3 in total

1.  Vascular pancreatic gastric fistula: a complication of colloidal 32P injection for nonresectable pancreatic cancer.

Authors:  Ignacio J Jaca Montijo; Vikas Khurana; Waleed M Alazmi; Stanley E Order; Jamie S Barkin
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

Review 2.  Mouse models expressing human carcinoembryonic antigen (CEA) as a transgene: evaluation of CEA-based cancer vaccines.

Authors:  Kenneth W Hance; Hasan E Zeytin; John W Greiner
Journal:  Mutat Res       Date:  2005-08-25       Impact factor: 2.433

Review 3.  Adjuvant treatment strategies for pancreatic cancer.

Authors:  Erika A Newman; Diane M Simeone; Michael W Mulholland
Journal:  J Gastrointest Surg       Date:  2006-06       Impact factor: 3.452

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.